Clinical Trials Browser

Phase 2 × Inflammatory Breast Neoplasms × Bevacizumab × Clear all

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2 Completed

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00016549 2017-07-02

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00957125 2016-09-08

PROMIX

Phase 2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01641406 2012-07-16

NACprotocol

Phase 2 Unknown

Breast Carcinoma In Situ, Carcinoma, Lobular, Inflammatory Breast Neoplasms